Novavax is trading at $11.65, up 5.86%, with no clear catalyst identified for the October 9 gain. - No fresh company-specific announcement surfaced in the search; recent coverage of an earlier vaccine-sector rally and pullback does not explain this session’s move. - Biotech-sector weakness ran counter to the gain, while supplied major-index moves were modest. - Available evidence points to an unclear, possibly stock-specific move—not a confirmed company, sector, or global catalyst.